share_log

Piper Sandler Maintains Overweight on LENZ Therapeutics, Maintains $36 Price Target

Benzinga ·  Aug 16 01:59  · Ratings

Piper Sandler analyst Joseph Catanzaro maintains LENZ Therapeutics (NASDAQ:LENZ) with a Overweight and maintains $36 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment